

ITM Ltd. (Group)

(ITM Group, Clinical Trial and Critical Care Medicine Advisor)

Zhiyong Peng, M.D., Ph.D.

BIOGRAPHY

Director, Wuhan IV Vitamin C Clinical Trials
Dept. Head, Critical Care Medicine, Zhongnan Hospital
Founder/Member, The First Dragon Foundation™ Board of Advisors

Zhiyong Peng, M.D., Ph.D. is the Director of the Department of Critical Care Medicine at Zhongnan Hospital of Wuhan University and is currently leading the world's first randomized controlled clinical trial to test the efficacy of intravenous ascorbate (vitamin C) therapy in treating severe acute respiratory infection in severe and critically ill COVID 19 patients. (<https://clinicaltrials.gov/ct2/show/NCT04264533>)

Based on his experience as a veteran critical care doctor using vitamin C during the SARS outbreak in 2003, and his knowledge of Dr. Paul Marik's success using intravenous vitamin C to dramatically reduce the mortality of septic shock, Dr. Peng hypothesized that high-dose vitamin C infusion could help improve the prognosis of patients with COVID 19.

Preliminary results of the Dr. Peng's clinical trials in Wuhan have shown a clear pattern that IV vitamin C improves organ function, with a trend toward improved survival in critically ill patients with COVID 19 -- mortality was reduced by more than 30 percent. However, because of a lack of new patients in China, the trial group of 50 patients was too small to provide statistically significant conclusions regarding overall survival benefit.

To meet the urgent need to connect with other academic ICU physicians in other countries still with active COVID19 pandemic to join Dr. Peng's randomized clinical trial, he has partnered with Mr. [Jack Craciun III](#), Chairman/CEO of ITM Ltd., (Group of Cos.) and the Founder/Chairman of the First Dragon Foundation™ and The Future of Medicine, Inc. (TFDF), in association with [Dr. Dwight McKee](#), a US Integrative Oncologist, and [Dr. Tang Jinlong, \(Ph.D. of Law and Economics\)](#) both of whom are Directors of The First Dragon Foundation™, Ltd. They are working together to expand the clinical trial into a multi-center ICU, multinational trial of a minimum of 300 patients.

In April, 2020, Dr. Zhiyong Peng joined the Board of Advisors of The First Dragon Foundation™ Ltd. and The Future of Medicine, Inc. In welcoming Dr. Peng to the Board of Advisors, Director Dwight L. McKee stated:

With the help of ITM in management, and ITM working with TFDF fundraising and communications, this humble vitamin, delivered by the high technology of modern medicine, may for the first time be proved to be lifesaving in the context of overwhelming viral infections, as well as in overwhelming bacterial infections.

This is Integrative Medicine at its finest, brought to the Gold Standard of modern medicine--the randomized controlled clinical trial, by Dr. Peng from the epicenter of this global Pandemic. China leads the way, with support from America. It is past time that humanity puts human welfare ahead of profit, particularly in healing and medicine.

Dr. Peng holds a double doctorate in anesthesiology from Wuhan Tongji Medical University and a doctorate in critical medicine from the Chinese University of Hong Kong. He has post-doctoral research experience at the Denver Medical Center of University of Colorado and the Department of Critical Care Medicine of University of Pittsburgh Medical Center in the United States.

He was the Assistant Professor at the Department of Critical Care Medicine of University of Pittsburgh Medical Center and specialist at Jackson Memorial Hospital in the United States. He has been engaged in intensive medicine for more than 20 years with in-depth research and rich clinical experience on acute kidney injury, sepsis organ function injury and blood purification treatment. He has presided over 2 sub-projects of major NIH (National Institutes of Health) research projects in the United States, is highly published in the US and China, and has won three awards from the American Enteral and External Nutrition Society and the American Academy of Critical Care Medicine

Professional Memberships and Associations:

Chinese Medical Association Critical Medicine Branch, Hubei Province Chairman-Elect
Deputy Chairman, Chinese Academy of Research Hospitals Critical Medicine Professional Committee
Standing Committee of the Chinese Medical Doctors Association of Critical Medicine Physicians
Neurological Surgery Expert Committee
Standing Committee of the In-Vitro Life Support Branch of the Chinese Medical Association
American Society of Critical Care Medicine (SCCM)
American Thoracic Society (ATS)
European Society of Anesthesiology (ESA)
American Society of Critical Medicine Scientific Review Committee
European Society of Acute Renal Injury Professional Committee
American NIH Project Review Expert
Ireland National Fund Review Expert
China National Natural Science Fund Review Expert
Editorial Board, Journal of Critical Care (USA) and Blood Purification (Europe).